Meeting
2021 ASCO Annual Meeting
Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.
Authors
Cara Amanda Mathews
Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, Providence, RI
Cara Amanda Mathews , Fiona Simpkins , Karen Anne Cadoo , Ying L Liu , Diane M. Provencher , Colleen McCormick , Adam ElNaggar , Alon D Altman , Lucy Gilbert , Destin Black , Nashwa Kabil , James Bennett , Jiefen Munley , Judy Yu , Carol Aghajanian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02983799
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5515)
DOI
10.1200/JCO.2021.39.15_suppl.5515
Abstract #
5515
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Olaparib treatment in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Phase II LIGHT study.
First Author: Karen Anne Cadoo
Poster
2017 ASCO Annual Meeting
A phase 2 study to assess olaparib by homologous recombination deficiency status in patients with platinum-sensitive, relapsed, ovarian, fallopian tube, or primary peritoneal cancer.
First Author: Karen Anne Cadoo
Poster
2022 ASCO Annual Meeting
Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.
First Author: Sandro Pignata
Poster
2023 ASCO Annual Meeting
Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).
First Author: Yoo Na Kim